Equity Overview
Price & Market Data
Price: $0.60
Daily Change: -$0.0014 / 0.23%
Range: $0.594 - $0.651
Market Cap: $50,785,620
Volume: 101,080
Performance Metrics
1 Week: 7.51%
1 Month: -30.60%
3 Months: -34.90%
6 Months: -58.78%
1 Year: -69.29%
YTD: -36.15%
Company Details
Employees: 152
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. It offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. The company's lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the potential treatment of autoimmune diseases and relapsed/refractory B-cell non-hodgkin's lymphoma. It also develops ADI-270, an armored gamma delta CAR T cell product candidate to treat multiple CD70+ solid tumor and hematological malignancies indications, with renal cell carcinoma. The company was founded in 2014 and is based in Boston, Massachusetts.